Liquid biopsy holds enormous potential in precision oncology—enabling non-invasive, real-time insights into tumor genomics that can guide more accurate treatment decisions. However, its global implementation is still limited by several key challenges.

This webinar will spotlight a strategic collaboration between SOPHiA GENETICS and AstraZeneca, focused on expanding the reach and impact of MSK-ACCESS® powered with SOPHiA DDM™. Through this partnership, technology and clinical expertise are being brought together to create more equitable access to cutting-edge cancer diagnostics around the world.

This session brings together scientific and clinical leaders to discuss their firsthand experiences and the broader implications of such collaborations for cancer care globally.

Why Attend?

While liquid biopsy is often discussed in the context of technical potential, this webinar explores what it takes to turn potential into practice—particularly in settings where access to liquid biopsy is limited.

Learning Objectives

By attending this session, you will:

Understand the technological and analytical foundations of MSK-ACCESS® powered with SOPHiA DDM™, and how it addresses key challenges in liquid biopsy testing such as accuracy, scalability, and reproducibility.

Explore the strategic steps and real-world considerations in building a decentralized global testing network—including how clinical, regulatory, and infrastructural barriers are being addressed collaboratively.

Hear firsthand experience from Synnovis as one of the early adopters of the solution—what implementation looked like, what worked, and how this impacted their clinical research workflows.